Andrew Davis

BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC.

Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC.

Part of iNova Pharmaceuticals (Australia) Pty Ltd., iNova Pharmaceuticals (Pty) Ltd. is a South African company that develops and markets a range of healthcare products. The company is based in Bedfordview, South Africa. The company's products include B-CAL-K2, a calcium and bone health supplement with clinically proven K2, and PregOmega Plus, a multivitamin and mineral supplement for pregnancy. The company is committed to promoting and manufacturing quality products that bring real benefits and comply with Good Manufacturing Practices (GMP).

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.